CMTM6 and triple-negative breast carcinoma: In our study, we detected the expression of CMTM6 and PD-L1 in triple-negative breast cancer, analyzed their relationship with clinicopathological characteristics, and explored the clinical significance of CMTM6 and PD-L1 in triple-negative breast cancer.